Perifosine (KRX-0401)

Catalog No.S1037 Synonyms: NSC639966

Perifosine (KRX-0401) Chemical Structure

Molecular Weight(MW): 461.66

Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

Size Price Stock Quantity  
USD 147 In stock
USD 270 In stock
USD 870 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 47 Publications

14 Customer Reviews

  • Tumor growth of 827 GSC-derived xenografts treated with an AKT inhibitor perifosine (30 mg/kg body weight). Twenty-three days after tumor implantation in mice, perifosine was administered by intraperitoneal injection (daily for 5 days). Error bars represent SD. Five mice per group, *p < 0.01.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    Immunoblot analysis of pY-STAT3, EZH2, AKT, and trimethylated H3K27 in lysates from xenograft tumors treated with an AKT inhibitor perifosine.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • Co-IP analysis of methylated STAT3 in GBM xenograft tumors treated with perifosine.AKT inhibition in vivo decreased STAT3 methylation and pY-STAT3, but increased global levels of H3K27 trimethylation.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

    IF staining of pS21 EZH2 and pY-STAT3 on the frozen sections of GBM xenografts treated with vehicle or perifosine. Nuclei were stained with DAPI. Bar represents 10 microns.

    Cancer Cell 2013 23, 839-52. Perifosine (KRX-0401) purchased from Selleck.

  • NRP-152 cells were transfected with Id1-luciferase reporter element as described in the figure and then incubated with±perifosine (10 nmol/L)  for 2 hours, followed by±LR3-IGF-I (10 nmol/L) for 24 hours. Cells were then treated with ±BMP4 and assayed for luciferase 2 hours later.

     

     

    Cancer Res 2010 70, 9106-9117. Perifosine (KRX-0401) purchased from Selleck.

     

    LAT2 is degraded by proteasomes after treatment with alkylphospholipids. A, 3-h treatment of NB4 cells before exposure to the proteasome inhibitor MG132 (10 μM) prevented the reduction of LAT2 induced by 25 μM ODPC. B, C, a similar effect was observed after exposure (30 min) of NB4 cells to the proteasome inhibitor MLN9708 (5 μM) followed by treatment with 25 μM ODPC (B) or 25 μM perifosine (C).

    Mol Cell Proteomics 2012 11(12), 1898-1912 . Perifosine (KRX-0401) purchased from Selleck.

  • Alkylphospholipid-induced morphological changes in HepG2 cells. Cell morphology was examined with an inverted microscope(20× original magnification). The morphology of HepG2 cells incubated with MEM/10% FBS is shown in the absence of any addition (control, A), or in the presence of 25 μM of HePC (B), edelfosine (C), ErPC (D) or perifosine (E) for 24 h. ErPC, erucylphosphocholine; FBS, fetal bovine serum; HePC, hexadecylphosphocholine; MEM, minimal essential medium.

     

     

    Brit J Pharmacol 2010 160, 355–366. Perifosine (KRX-0401) purchased from Selleck.

    Knockdown of BRCA1 sensitizes cells to PI3K/AKT pathway inhibitors. MCF7 cells transfected with either BRCA1-siRNA or control-siRNA were treated with increasing amounts of inhibitors targeting the PI3K/AKT pathway for 48 h in triplicate. Viable cells were measured by MTT assay.

    Mol Carcinog 2012 ahead of print. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting analysis demonstrating Ser473p-Akt and total Akt levels in HepG2 cells and Bel-7402 cells treated with increasing concentrations of perifosine for 24 h. Betaactin served as loading control. Bands were analyzed by Glyco Band-Scan software. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05,** P<0.01 vs. control, Student,s t test

     

     

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    Induction of apoptosis in hepatoma cells by treatment for 48 h with 10 μM perifosine. The treated cells were stained with DAPI and the apoptotic morphological changes in the nuclear chromatin were observed under a fluorescent microscope.

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

  • Western blotting assay showing cleavage of caspase-3, caspase-9 and PARP in response to perifosine treatment in hepatoma cells. Each bar corresponds to the mean ±SD for at least three independent experiments. * P<0.05, ** P<0.01 vs. control, Student,s t test

    Cytotechnology 2010 62, 449-460. Perifosine (KRX-0401) purchased from Selleck.

    This chart showed the change of the stable transfection cells in centrosome separation after the cells were treated with perifosine(1 μM)  6 hours, 12 hours and 24 hours. "C" means the control group, and "P" means the group treated with perifosine

    2010 Zhao Jing PHD Medical College of Peking University. Perifosine (KRX-0401) purchased from Selleck.

  • TEIF (telomerase transcriptional elements-interacting factor)gene is a novel human gene and cloned from the expression library of  HeLa cell through the hTERT promoter-based yeast one-hybrid assay. And now we are trying to find the interaction between TEIF and the EGF pathway.

     

     

    2010 Zhao Jing PHD Medical College of Peking University . Perifosine (KRX-0401) purchased from Selleck.

     After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of Perifosine for 3h,followed by 15-minute  stimolation of 100ng/ml EGF.

     

     

     

    2010 Dr. Zhang of Tianjin Medical University. Perifosine (KRX-0401) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.
Targets
Akt [1]
(MM.1S cells)
4.7 μM
In vitro

Perifosine develops anti-proliferative properties with IC50 of 0.6-8.9 μM in immortalized keratinocytes (HaCaT), and head and neck squamous carcinoma cells. [1] Perifosine strongly reduces phosphorylation levels of Akt and extracellular signal-regulated kinase (Erk) 1/2, induces cell cycle arrest in G1 and G2, and causes dose-dependent growth inhibition of mouse glial progenitors. [2] Perifosine (10 μM) completely inhibits the phosphorylation of Akt in MM.1S cells. [3] A recent study demonstrates Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
T24 BC  NF7MU|NHfW6ldHnvckBCe3OjeR?= Mo\YNE42NzFxMj61JO69VQ>? MWSzJIg> NXfIZlcxemWmdXPld{B1cGViYnHzZYwhS0JidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9vKGyndnXsd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MUSyOlA6Pzh5Mx?=
T24 BC  MWXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIL1dJgxNjVxMT:yMlUh|ryP M{LoV|I1KGh? MV\lcohidmOnczDzc5Ji\mWwaXKtbY5lfWOnZDDj[YxtKH[rYXLpcIl1gSCmZXPy[YF{\Q>? NFXPd4IzPjB7N{i3Ny=>
T24 BC  NHfINlFCeG:ydH;zbZMhSXO|c3H5 MUmyMlUh|ryP NYfFWnFwOjRiaB?= Mo\Nd4Vve2m2aYrld{BDSyClZXzsd{B1dyC|b4Lh[oVvcWJvaX7keYNm\CCjcH;weI91cWQEoB?= MXmyOlA6Pzh5Mx?=
HepG2 NHjPSWVHfW6ldHnvckBCe3OjeR?= M4\SR|IxyqEQvF2= NVzadY1WOjUEoHi= NE\IdZdxem:mdXPld{BidiCrboTlcpNmKGO7dH;wcIF{dWmlII\hZ5VwdGm8YYTpc44h[2:{cnXzdI9v\GmwZzD0c{BiKG6xdHHicIUh\GmuYYTheIlwdiCxZjD0bIUhTVJiY3nzeIVzdnN? M3PTclI2QTN2MkOy
U-87 MG  NGP6PItHfW6ldHnvckBCe3OjeR?= MlizNlDDqM7:TR?= MoWzNlTDqGh? NGXWXGlqdmO{ZXHz[ZMh\G:3YnzlMY1mdWK{YX7lJIJwfW6mIIP0dpVkfHW{ZYO= MoPPNlU6OzR{M{K=
HepG2 NVHneZF4TnWwY4Tpc44hSXO|YYm= MknmNlDDqM7:TR?= Mk[0Ok8zPCCq M3PofYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIFzDN{1KUSClb4Ty[YF1\WRid3n0bEBEWQ>? NELiVoIzPTl|NEKzNi=>
U-87 MG  M1HFSWZ2dmO2aX;uJGF{e2G7 NHL0VmczOMLizszN NVzLVoV2Pi9{NDDo MlTCbY5kemWjc3XzJJRp\SCuZY\lcJMhd2ZiTFOzMWlKKGOxdILlZZRm\CC5aYToJGNS MkLYNlU6OzR{M{K=
HepG2 MYHGeY5kfGmxbjDBd5NigQ>? MVSyNOKh|ryP MUS2M|I1KGh? MkXN[IVkemWjc3XzJGxEOy2LSTDk[Ydz[WSjdHnvcuKh\nKxbTC2JIg> NU\nbVNnOjV7M{SyN|I>
U-87 MG  NGXXNG9HfW6ldHnvckBCe3OjeR?= NEf0SZozOMLizszN MkTFOk8zPCCq MUDpcoNz\WG|ZYOgeIhmKGG3dH;wbIFocWNiZnz1fEAh[XRiNjDoJJdpcWynIHnubIljcXS|IITobZMh\my3eDDheEAzPGh? MX6yOVk{PDJ|Mh?=
HepG2 NHK5RYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGyNE81OCEQvF2= M3fHbVI1NzR6IHi= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MojwNlU6OzR{M{K=
U-87 MG  NV3OS2tMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmyNE81OCEQvF2= M3zOVFI1NzR6IHi= MXzpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MYSyOVk{PDJ|Mh?=
A549 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LGRlAvOy1zMDFOwG0> Mk\zNlQwPzJiaB?= NGm2dXRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NEDIS4kzPTZ7N{i5PS=>
H460 NInRcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\iSHIxNjNvMUCg{txO MWKyOE84OiCq Mmq3bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MoXMNlU3QTd6OUm=
A549 NEewT3dCeG:ydH;zbZMhSXO|c3H5 NX;lT|hEOS9|IN88US=> NWXiWIV5PDhiaB?= M2nGe4lv\HWlZYOgZZBweHSxc3nz NHyyNpYzPTZ7N{i5PS=>
H460 NUnhPHRZSXCxcITvd4l{KEG|c4PhfS=> MlTZNU8{KM7:TR?= MUG0PEBp MkGxbY5lfWOnczDhdI9xfG:|aYO= MXeyOVY6Pzh7OR?=
A549 NHjFVnhHfW6ldHnvckBCe3OjeR?= NXW3PWxGOyEQvF2= MXu4JIg> M2HEfIJtd2OtczDBT3Qh[WO2aY\heIlwdg>? NYX6[WdWOjV4OUe4PVk>
H460 M4\ZbGZ2dmO2aX;uJGF{e2G7 MWizJO69VQ>? M4HPeFghcA>? NVTmWIZi[myxY3vzJGFMXCCjY4TpeoF1cW:w NI\QTlIzPTZ7N{i5PS=>
A549 NGPJd29HfW6ldHnvckBCe3OjeR?= Mlv6N{DPxE1? MmHFPEBp Mk\SZoxw[2u|IH3UU3JEOSxiYX7kJGVTUy2PQWDLJIFkfGm4YYTpc44h[2:vYnnu[YQhf2m2aDDNSWsuOTZ{ MknhNlU3QTd6OUm=
H460 Ml74SpVv[3Srb36gRZN{[Xl? NFfhVIY{KM7:TR?= MUW4JIg> NVnTdnNr[myxY3vzJI1VV1KFMTygZY5lKEWUSz3NRXBMKGGldHn2ZZRqd25iY3;tZolv\WRid3n0bEBOTUtvMU[y MknUNlU3QTd6OUm=
RMG1 Mo[2R4VtdCCYaXHibYxqfHliQYPzZZk> M{XnbFEuOzBizszN MVS3NkBp MXnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MkPtNlU2OTlzNEi=
RMG2 Mn3UR4VtdCCYaXHibYxqfHliQYPzZZk> NITRWnYyNTNyIN88US=> NFXidXg4OiCq NWSyOYo5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy M{DpbVI2PTF7MUS4
KOC7C NFzvTXhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGe1W4kyNTNyIN88US=> NUXPZlU5PzJiaB?= M3fDWYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= M1\VOlI2PTF7MUS4
HAC2 M3zhbGNmdGxiVnnhZoltcXS7IFHzd4F6 NGHSVWoyNTNyIN88US=> NGTOTIw4OiCq MYnk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? NGDGR40zPTVzOUG0PC=>
RMG2 M{X2bmNmdGxiVnnhZoltcXS7IFHzd4F6 MWqxMVMxKM7:TR?= M4X0XVQ5KGh? NEPH[XVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NF:0ZZozPTVzOUG0PC=>
OVISE MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYTpO4tmOS1|MDFOwG0> M2j4PFQ5KGh? NX71b2No\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy NUm3ZXdMOjV3MUmxOFg>
SKOV3 Mly0R4VtdCCYaXHibYxqfHliQYPzZZk> MmX4NU0{OCEQvF2= NVXXOWFMPDhiaB?= M{niTYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NWTMflRSOjV3MUmxOFg>
A2780 NXH0Z3BIS2WubDDWbYFjcWyrdImgRZN{[Xl? MYWxMVMxKM7:TR?= MkTSOFghcA>? NWrkcXRN\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MXqyOVUyQTF2OB?=
RMG1 Ml\vRZBweHSxc3nzJGF{e3OjeR?= NF3iZnQ{OCEQvF2= NUTrUpdMOjRiaB?= M4rFUolv\HWlZYOgZZBweHSxc3nz NGHjS5czPTVzOUG0PC=>
RMG2 MYLBdI9xfG:|aYOgRZN{e2G7 NYHaTVBGOzBizszN NFm4R24zPCCq MYrpcoR2[2W|IHHwc5B1d3Orcx?= NXG4UHZmOjV3MUmxOFg>
HCC1806 NIHRe5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjxNE0yOCEQvF2= M4PYSFQ5KGh? M2fOSWVEPTB;Mj64OQKBkcLz4pEJNE4xPyEQvF2= M{PVc|I2Ojl|NUe2
MDA-MB-231  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i4PFAuOTBizszN NXTuN2ZlPDhiaB?= NYq1SZlKTUN3ME2xMlE{6oDLwsJihKkxNjB5IN88US=> NEnWeXIzPTJ7M{W3Oi=>
GL-1 NHvRfZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXNdnVjOC5z4pETNVAx6oDLzszN M1LaOFQ5KGh? NEjr[VdKSzVyPUmuPVEh|ryP M37sUlI1QDhzNUC4
CLBL-1 Ml\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFniXnoxNjIkgKOxNFDjiIoQvF2= NFHkc3Q1QCCq NXSxVmI{UUN3ME2zN{4xKM7:TR?= M4XIbVI1QDhzNUC4
UL-1 NHzSWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKwMlHjiJNzMEFihKnPxE1? MYi0PEBp M1\3V2lEPTB;Nz6wNUDPxE1? M1nJbFI1QDhzNUC4
Ema M2fsOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWSwMlHjiJNzMEFihKnPxE1? NYTDZ3M4PDhiaB?= MmXuTWM2OD13OD63JO69VQ>? M{nHVlI1QDhzNUC4
PANC-1 NXnF[Io{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHmNE0zPSEQvF2= NFe4XVk4OiCq M2PVT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz Ml\sNlQ2OTl5NUG=
MIA MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuwMVI2KM7:TR?= MWK3NkBp NVW2c3FPcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MVGyOFUyQTd3MR?=
AsPC-1 MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\CV|hrOC1{NTFOwG0> MXu3NkBp M3rQU4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NGXz[mkzPDVzOUe1NS=>
PANC-1 NWSzd3dOTnWwY4Tpc44hSXO|YYm= MnrTNE42KM7:TR?= NILXfGwzPCCq NYrhbHA4cW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi NITzbXozPDVzOUe1NS=>
MIA MlTzSpVv[3Srb36gRZN{[Xl? NYXnd21[OC53IN88US=> MnrqNlQhcA>? NHjnco9qdmirYnn0d{BCc3RuIGO2T|EtKGGwZDDFdosyNzJicHjvd5Bpd3K7bHH0bY9vyqB? NFHET5AzPDVzOUe1NS=>
AsPC-1 NHLDRm5HfW6ldHnvckBCe3OjeR?= NY\GXFM4OC53IN88US=> M3vyPVI1KGh? NUnTPYticW6qaXLpeJMhSWu2LDDTOmsyNCCjbnSgSZJsOS9{IIDoc5NxcG:{eXzheIlwdsLi M{fRNFI1PTF7N{Wx
U87MG M3S1SmNmdGxiVnnhZoltcXS7IFHzd4F6 NVXTZmRUOC1{NTFOwG0> NUDkc2kyOjRvOU[gbC=> MYXk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MWSyOFA3PTV{Mh?=
SGC7901  M1j5PGZ2dmO2aX;uJGF{e2G7 M1XmclAvPzVxMUFCpO69VQ>? MknqOFghcA>? MlPS[IVkemWjc3XzJJAuSWu2IDjT[ZIhPDd|KTygdE1IW0t|zsKgLHNmeiB7KTygZY5lKENvTWnDJIxmfmWuc9Mg MmHZNlM6OTJ{NE[=
MGC803  M2P4fGZ2dmO2aX;uJGF{e2G7 NUOw[YNkOC55NT:xNOKh|ryP M1LseVQ5yqCq NF\He5hl\WO{ZXHz[ZMheC2Da4SgLHNmeiB2N{OpMEBxNUeVS{ROtkApW2W{IEmpMEBidmRiQz3NXWMhdGW4ZXzzxsA> MW[yN|kyOjJ2Nh?=
TykNu M3LOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKydVBKSzVyPUOuOUDPxE1? NV3nb3JuOjN6N{ewNVI>
TykNuR M4nKNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfpTWM2OD13LkWg{txO M1LxSVI{QDd5MEGy
M41 NVzYW|FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ2Lkeg{txO NIPINGIzOzh5N{CxNi=>
M41R MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLMUpdMUUN3ME2xPU45KM7:TR?= NHLkXZAzOzh5N{CxNi=>
OVCAR8 NEDycYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\jZYhlUUN3ME2zNU4yKM7:TR?= M3PVcVI{QDd5MEGy
HeyA8 NFL6TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEK4eIlKSzVyPUK0MlMh|ryP M1LNcFI{QDd5MEGy
A2780CP NWLafVV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTdwNjFOwG0> NFLweWMzOzh5N{CxNi=>
OVCAR5 NVrIcWg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;hPI5KSzVyPU[uO{DPxE1? NXmyVI9DOjN6N{ewNVI>
A2780S MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXXZppKSzVyPUG0MlUh|ryP NYOyeFNGOjN6N{ewNVI>
MCAS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTF{LkWg{txO MWeyN|g4PzBzMh?=
NCI-H727 MmHlR4VtdCCYaXHibYxqfHliQYPzZZk> MX:wMVExOCEQvF2= MoHGNlQwPzJiaB?= Mom3[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy NEPafWMzOjR7OUSzOy=>
GOT1 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MonTNE0yODBizszN NHXIO3QzPC95MjDo MWLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZo91cCCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MUOyNlQ6QTR|Nx?=
BON1 NVnNUm9JS2WubDDWbYFjcWyrdImgRZN{[Xl? NUf4TXJmOC1zMECg{txO M2LyRlI1Nzd{IHi= NWDTS2Vt\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHig[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnRibXHucoVz NH7BfpAzOjR7OUSzOy=>
BON1 NHnhS21CeG:ydH;zbZMhSXO|c3H5 MoXENE0yOCEQvF2= NHGwXpAzPCCq MXzpcoR2[2W|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7 MVOyNlQ6QTR|Nx?=
BON1 NHTiT5JHfW6ldHnvckBCe3OjeR?= NGG2NHE4NjVxMUCg{txO MlfCPEBp NWPtSYdE\GWlcnXhd4V{KHSqZTDlfJBz\XO|aX;uJI9nKHSqZTDhcpRqNWGyb4D0c5Rq[yCycn;0[YlveyCEQ1yyJIFv\CCEY3ytXGw> NH3QcmMzOjR7OUSzOy=>
Kasumi-1 M{DhT2NmdGxiVnnhZoltcXS7IFHzd4F6 NGXVVHgxNTJyIN88US=> Moq5NlQwPDhiaB?= NITYe5Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI> MVOyNlQxPzJ{OB?=
HL-60 MnntR4VtdCCYaXHibYxqfHliQYPzZZk> M1GwXlAuOjBizszN MWqyOE81QCCq M3:2R4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=> NFrYOYgzOjRyN{KyPC=>
Kasumi-1 NHTrVlFCeG:ydH;zbZMhSXO|c3H5 M3XmOVExKM7:TR?= NGHyRVYzPCCq NIH5UGxqdmS3Y3XzJIFxd3C2b4Ppdy=> NFvPZogzOjRyN{KyPC=>
HL-60 NWjWPIc4SXCxcITvd4l{KEG|c4PhfS=> MWWxNEDPxE1? MX[yOEBp MkDHbY5lfWOnczDhdI9xfG:|aYO= Ml7nNlI1ODd{Mki=
Kasumi-1 NUPEZ3hXTnWwY4Tpc44hSXO|YYm= NWP6cllLOi53L{WvNVAh|ryP MmXsNlQhcA>? M3XwOoRm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? MWiyNlQxPzJ{OB?=
HL-60 NHLD[3NHfW6ldHnvckBCe3OjeR?= MoDENk42NzVxMUCg{txO NIrkbFkzPCCq M3jEZ4Rm[3KnYYPld{BCc3RiYX7kJJAuSWu2IHzleoVte8LiZH;z[U1l\XCnbnTlcpRtgQ>? NGXKOlQzOjRyN{KyPC=>
Kasumi-1 MV7GeY5kfGmxbjDBd5NigQ>? MWqyMlUwPS9zMDFOwG0> MXeyOEBp M4raSYlv\HWlZYOgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCMTluxM|IhcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MWeyNlQxPzJ{OB?=
HL-60 MlzmSpVv[3Srb36gRZN{[Xl? NH\MN3MzNjVxNT:xNEDPxE1? M1nwc|I1KGh? NULOOlFqcW6mdXPld{B1cGVicHjvd5Bpd3K7bHH0bY9vKG:oIFrOT|EwOiCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? Mo\ONlI1ODd{Mki=
K562 NFTZeHpHfW6ldHnvckBCe3OjeR?= NYnxXlRmOjBizszN NUTUeG82PDhiaB?= NIHBNWxqdmS3Y3XzJIF2fG:yaHHnfeKh NILJV2UzOjRyN{KyPC=>
OCUT1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMlEuOyEQvF2= M1HqU|Uh\A>? M1WyV4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz MXmyNlA6ODJ5MR?=
K1 NXfzUI1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjMbYExNjFvMzFOwG0> M2POeFUh\A>? M1LUdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz M364ZVIzODlyMkex
OCUT1 NYDoW2N4TnWwY4Tpc44hSXO|YYm= M4Pa[lMh|ryv NH;CWoQzPCCq MlzIZ4F2e2W|IHGg[JJidWG2aXOgbY5kemWjc3WgbY4hTzJxTTDwbIF{\Q>? MUeyNlA6ODJ5MR?=
CaOV3 NYOxXWtQS2WubDDWbYFjcWyrdImgRZN{[Xl? NEXsbWQyNzVxMUCg{txO MX[0PEBp MUDk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJiY3;0doVifGWmIIfpeIgheGGlbHn0ZZhmdA>? NVr3V|ljOjF5N{WwOVQ>
SKOV3 NV;CVY1qS3m2b4TvfIlkcXS7IFHzd4F6 NUe3fGljPSEQvF2= NX7jR|F{PDhiaB?= M{PnZoVvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NYXofXZsOjF5N{WwOVQ>
A2780 NWHpfXp4S3m2b4TvfIlkcXS7IFHzd4F6 NF7ZO4g2KM7:TR?= NH7ncnY1QCCq NX7oTGtC\W6qYX7j[ZMheGGlbHn0ZZhmdCCrbnT1Z4VlKG:4YYLpZY4h[2GwY3XyJINmdGxiZHXheIjDqA>? NV;vR2VSOjF5N{WwOVQ>
HT-29  MmPWR5l1d3SxeHnjbZR6KEG|c3H5 M1;4dFUh|ryP NU\Ve|VzPDhiaB?= M1jU[4VvcGGwY3XzJJBi[2yrdHH4[YwhcW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA> NX3K[WNGOjF5N{WwOVQ>
A498 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;UXFAuPDBizszN NFjFdHQ4OiCq NFfKZ2lqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? M1XoU|IyPjR2MEWw
CAKI-1 NHHvS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXo[IYxNTRyIN88US=> M33RdVczKGh? M1vIfGlEPTC-MUCg{txO M4raNFIyPjR2MEWw
769-P MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfSe49nOC12MDFOwG0> MYK3NkBp MWnJR|UxhjVvMUCg{txO NIDYfVAzOTZ2NEC1NC=>
786-0 NXLXTVZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqwMVQxKM7:TR?= NFf5dJc4OiCq MnLoTWM2OH53IN88US=> MoLBNlE3PDRyNUC=
786-O MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[5ZWpUOC1{MDFOwG0> M3juSFczKGh? MlzIbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MnPWNlE3PDRyNUC=
CAKI-1 NWjvPYxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPKTnoxNTJyIN88US=> MoHUO|IhcA>? Mnv4bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> NXjqOYpxOjF4NESwOVA>
769-P NV7UVJN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;1UpIxNTJyIN88US=> M3PyfVczKGh? MXrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> M2\iPVIyPjR2MEWw
A498 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnndpJDOC1{MDFOwG0> NVPaV2MxPzJiaB?= MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> NGDvNWIzOTZ2NEC1NC=>
CWR22RV1 Mn7zR4VtdCCYaXHibYxqfHliQYPzZZk> NEnqTZQyOCEQvF2= MVOyOEBp MofNbY5kemWjc3XzJJNmdnOrdHn2bZR6KG:oIHj1cYFvKEOZUkKyVnYyKGOnbHzzJJRwKHKjZHnheIlwdg>? NFvWS2czOTR7NkK3Ny=>
CWR22RV1 M33SUGFxd3C2b4Ppd{BCe3O|YYm= M1HCXFExKM7:TR?= MXmyOEBp MXrlcohidmOnczDyZYRq[XSrb36gbY5lfWOnZDDhdI9xfG:|aYO= M{T5bFIyPDl4Mkez
CWR22RV1 MXfGeY5kfGmxbjDBd5NigQ>? NX\TcIh4PSEQvF2= Ml;KNlQhcA>? NWXVdmltemWmdXPl[EBxcG:|cHjvdplt[XSrb36gc4YhSWu2IIPp[45q\mmlYX70cJk> NGTqdmgzOTR7NkK3Ny=>
HepG2  NELFNGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\YNmE2NzFyL{KwM|QxKM7:TR?= MWWyOE81QC95MjDo NFTUemNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MkjjNlA5PDJ2MkW=
Bel-7402 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLGWoNDPS9zMD:yNE81OCEQvF2= NIXLb|QzPC92OD:3NkBp NEjGXFNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= NXjndnVvOjB6NEK0NlU>
HepG2  NX3GR2lRTnWwY4Tpc44hSXO|YYm= NYfjcHlTPS9zMD:yNEDPxE1? MkXvNlQhcA>? NHHGe3dz\XO3bITzJIlvKHSqZTDhZ4N2dXWuYYTpc44hd2ZiY3XscEBvfW2kZYKgbY4hfGinIFeyM20heGijc3W= MkjTNlA5PDJ2MkW=
Bel-7402 NWXrZ2F3TnWwY4Tpc44hSXO|YYm= MUi1M|ExNzJyIN88US=> NX;2O4JPOjRiaB?= M3XRSJJme3WudIOgbY4hfGinIHHjZ5VufWyjdHnvckBw\iClZXzsJI52dWKncjDpckB1cGViR{KvUUBxcGG|ZR?= NVf5[4JwOjB6NEK0NlU>
HepG2  MmK5RZBweHSxc3nzJGF{e3OjeR?= M1zUTFUwOTBxMkCg{txO NWj1R3NNOjRxNEigbC=> M3Ky[Ilv\HWlZYOgZZBweHSxc3nzJIF1KHSqZTDsc45oNXSrbXWg[Zhxd3O3cnW= NFzqboQzODh2MkSyOS=>
Bel-7402 MkLFRZBweHSxc3nzJGF{e3OjeR?= NE\zdGE2NzFyL{KwJO69VQ>? NEXaPWszPC92ODDo NHXSWVZqdmS3Y3XzJIFxd3C2b4Ppd{BifCC2aHWgcI9v\y22aX3lJIV5eG:|dYLl NYn1bo1ROjB6NEK0NlU>
OAW-42 NFnrZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXWwMVQxKM7:TR?= MXK3NuKhcA>? NIHKeWFKSzVyfkGwJO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= MW[yNFQxPTJ7Nh?=
PA-1  NWPSTHJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojyNE01OCEQvF2= M4C1SFczyqCq NIHQVmtKSzVyfkK1JO69VSxiaX7obYJqfHNiY3XscEBoem:5dHigbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK= NIL1VZUzODRyNUK5Oi=>
SKOV3  M2DaS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW5O45vOC12MDFOwG0> MmPnO|LDqGh? M{Dqd2lEPTC-M{Cg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MWmyNFQxPTJ7Nh?=
A2780 NIi0NFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P4elAuOjBizszN MXy0PE84OiCq NIrzem1KSzVywrC9xsA{yqEQvH2= NX:zNIhYOjB2MEWyPVY>
A2780cis  M1\LO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHTV2lmOC1{MDFOwG0> MWS0PE84OiCq NH3MOXFKSzVywrC9xsA3yqEQvH2= Mo\DNlA1ODV{OU[=
SKW6.4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXyyMVExyqEQvF2= M{nReVQ5yqCq NUL1fW5DcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? Mm\uNlAyOzB7NkC=
MAVER M4DK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[wdlR5Oi1zMNMg{txO MUK0POKhcA>? NGnN[GdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? MlrWNlAyOzB7NkC=
BJAB M2XF[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPUS3ljOi1zMNMg{txO NUnRbnVwPDkEoHi= NIW3bHdqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>? NH35UWEzODF|MEm2NC=>
OCI M{nCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2e1NVIuOTEEoN88US=> Mnm3OFjDqGh? MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MlniNlAyOzB7NkC=
MOLM M{LoOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfmTI9VOi1zMNMg{txO NHi0ZnY1QMLiaB?= MVrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MX:yNFE{ODl4MB?=
HL-60 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX[yMVExyqEQvF2= NYLyU45HPDkEoHi= M1PITYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz NFHOeoszODF|MEm2NC=>
SKW6.4 NITTUG9CeG:ydH;zbZMhSXO|c3H5 M{nB[FExyqEQvF2= NXTvN5NJOjRxNEigbC=> NGnWe3hqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MmC4NlAyOzB7NkC=
MAVER M3ywWmFxd3C2b4Ppd{BCe3O|YYm= M4HhdlExyqEQvF2= MUeyOE81QCCq M1v3Z4lv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= MmXrNlAyOzB7NkC=
BJAB MkHqRZBweHSxc3nzJGF{e3OjeR?= NXTMN4lkOTEEoN88US=> NYLtRmM{OjRxNEigbC=> M1[zbIlv\HWlZYOgZZBweHSxc3nzJJRqdWVvZHXw[Y5l\W62bIm= M1Ln[VIxOTNyOU[w
OCI M1y2R2Fxd3C2b4Ppd{BCe3O|YYm= M3TNPVExyqEQvF2= NWfydHNuOjRxNEigbC=> NH7WVWlqdmS3Y3XzJIFxd3C2b4Ppd{B1cW2nLXTldIVv\GWwdHz5 MonZNlAyOzB7NkC=
MOLM M1rETmFxd3C2b4Ppd{BCe3O|YYm= M2jmSlExyqEQvF2= MYeyOE81QCCq NX7FXZc5cW6mdXPld{BieG:ydH;zbZMhfGmvZT3k[ZBmdmSnboTsfS=> MYWyNFE{ODl4MB?=
HL-60 MlTkRZBweHSxc3nzJGF{e3OjeR?= NIjMXG0yOMLizszN NUe4VZF4OjRxNEigbC=> MXXpcoR2[2W|IHHwc5B1d3OrczD0bY1mNWSncHXu[IVvfGy7 NGHYOowzODF|MEm2NC=>

... Click to View More Cell Line Experimental Data

In vivo Perifosine combining with temozolomide reduces tumor proliferation (a PDGF-driven gliomagenesis) in vivo. The results indicate that Perifosine is an effective drug in gliomas in which Akt and Ras-Erk 1/2 pathways are frequently activated, and may be new candidate for glima treatment in the clinic. [2] Both oral daily and weekly administration of Perifosine significantly reduce human MM tumor growth and increase survival, compared with control animals treated with PBS vehicle only. [3] Perifosine induces thrombocytosis and leukocytosis and increases myelopoiesis in murine marrow and spleen, whereas it causes apoptosis in myeloma xenografts. [5]

Protocol

Kinase Assay:[3]
+ Expand

Akt kinase assay:

MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
Cell Research:[2]
+ Expand
  • Cell lines: Human glioma cell lines
  • Concentrations: 0, 15, 30 and 45 μM
  • Incubation Time: 48 hours
  • Method: Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.
    (Only for Reference)
Animal Research:[3]
+ Expand
  • Animal Models: MM.1S MM cells are inoculated subcutaneously in the right flank of Beige-nude-xid (BNX) mice (5 to 6 weeks old).
  • Formulation: 0.9% NaCl solution
  • Dosages: 250 mg/kg/wk or 36 mg/kg/d
  • Administration: Oral gavage
    (Only for Reference)

Solubility (25°C)

In vitro Ethanol 15 mg/mL (32.49 mM)
Water 8 mg/mL (17.32 mM)
DMSO <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 461.66
Formula

C25H52NO4P

CAS No. 157716-52-4
Storage powder
in solvent
Synonyms NSC639966

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02238496 Active, not recruiting Brain Tumor, Recurrent|Glioblastoma|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Mixed Glioma Andrew Lassman|Pfizer|AEterna Zentaris|Columbia University July 2014 Phase 2
NCT01224730 Unknown status Cancer AEterna Zentaris January 2012 Phase 1
NCT01097018 Completed Colorectal Cancer AEterna Zentaris April 2010 Phase 3
NCT01049841 Active, not recruiting Pediatric Solid Tumors Memorial Sloan Kettering Cancer Center|University of Wisconsin, Madison|Duke University|NATL COMP CA NETWORK|Pfizer|AEterna Zentaris January 2010 Phase 1
NCT01051557 Active, not recruiting Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Neoplasm National Cancer Institute (NCI) January 2010 Phase 1|Phase 2
NCT01002248 Terminated Multiple Myeloma AEterna Zentaris|Dana-Farber Cancer Institute December 2009 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy Perifosine (KRX-0401) | Perifosine (KRX-0401) supplier | purchase Perifosine (KRX-0401) | Perifosine (KRX-0401) cost | Perifosine (KRX-0401) manufacturer | order Perifosine (KRX-0401) | Perifosine (KRX-0401) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID